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EstradiolParkinson's disease (PD) is characterized by a selective degeneration of nigrostriatal dopaminergic pathway.
Epidemiological studies revealed a male predominance of the disease that has been attributed to the female
steroid hormones, mainly the estrogen. Estrogen neuroprotective effects have been shown in several studies,
however the mechanisms responsible by these effects are still unclear. Previous data from our group revealed
that glial cell line-derived neurotrophic factor (GDNF) is crucial to the dopaminergic protection provided by
17β-estradiol, and also suggest that the intracellular estrogen receptors (ERs) are not required for that neuropro-
tective effects.
The present study aimed to investigate the contribution of the G protein-coupled ER (GPER) activation in
estrogen-mediated dopaminergic neuroprotection against an insult induced by 1-methyl-4-phenylpyridinium
(MPP+), and whether GPER neuroprotective effects involve the regulation of GDNF expression. Using primary
mesencephalic cultures, we found that GPER activation protects dopaminergic neurons from MPP+ toxicity in
an extent similar to the promoted by a 17β-estradiol. Moreover, GPER activation promotes an increase in
GDNF levels. Both, GDNF antibody neutralization or RNA interference-mediated GDNF knockdown prevented
the GPER-mediated dopaminergic protection veriﬁed in mesencephalic cultures challenged with MPP+. Overall,
these results revealed that G1, a selective agonist of GPER, is able to protect dopaminergic neurons and that GDNF
overexpression is a key feature to GPER induced the neuroprotective effects.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is a neurodegenerative disorder, mainly
characterized by the progressive loss of dopaminergic neurons in the
substantia nigra pars compacta (SNc). As a result, a decrease of striatal
dopamine (DA) occurs, leading to motor manifestations. Epidemiologi-
cal studies indicate a higher occurrence of the disease in men than inr; DA, dopamine; E2, 17β-estra-
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gmail.com (D. Bessa-Neto),women [1–3]. In spite of the causes for this gender difference that re-
main under discussion, a protective effect of estrogen is widely recog-
nized. It was shown that both a longer exposure to the endogenous
steroids and estrogen replacement therapy are related with a reduced
risk of PD and lower severity of symptoms [4,5]. Moreover, a neuropro-
tective role of estrogen in the nigrostriatal dopaminergic system is well
supported by in vitro and in vivo studies using different toxin models,
namely 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [6,7]
and 6-hydroxydopamine (6-OHDA) [8–10]. Regardless of the proved
beneﬁcial effects of estrogen on the nigrostriatal pathway, humans'
treatment with estrogen is limited by the side effects reported after
long-term hormone exposure, mainly due to activation of estrogen re-
ceptors (ERs) [11]. Taking into account these limitations, alternative tar-
gets with similar neuroprotective potential are attracting some interest,
namely theG protein-coupled ER (GPER). GPER is located at extranucle-
ar sites, including the plasma membrane, endoplasmatic reticulum and
Golgi complex of neurons [12–15]. GPER is not only involved in rapid
signaling effects, but also in transcriptional responses triggered by
estrogen [16]. Importantly, studies using GPER knockout mice have
reported that the reproductive organs of knockoutmice did not present
detectable defects [15,17–19]. Moreover, GPER activation has not been
associated with obvious effect in reproductive function [20], which
represents an important advantage against the activation of the nuclear
ERs.
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neuroprotective effects of estrogen, however existent reports re-
vealed a neuroprotective effect of GPER activation in different
types of neurons [21–24]. Regarding dopaminergic neurons, to the
best of our knowledge there is only one study showing that the
selective GPER agonist (G1) is as successful as estradiol to protect
nigrostriatal dopaminergic neurons from MPTP-induced toxicity. In
support of this, GPER antagonist (G15) use conﬁrmed the role of
GPER in mediating estradiol-induced neuroprotection since it was
able to prevent the neuroprotective effect induced by both G1 and
estradiol [25].
It is generally accepted that some of the effects produced by estrogen
may be indirect and result from the action of several key effectors.
Amongmany candidates, neurotrophic factors constitute major players
in neuroprotection, and current evidences indicate that 17β-estradiol
(E2) is able to regulate neurotrophic factor expression, namely brain-
derived neurotrophic factor (BDNF) and glial cell line-derived neuro-
trophic factor (GDNF) [10,26–29]. Moreover, co-localization of estrogen
receptor and neurotrophic factors suggests that these molecules may
act together to regulate the expression of speciﬁc genes that promote
neuronal survival [30,31]. Previous data from our group revealed that
GDNF up-regulation is crucial to estradiol-induced dopaminergic pro-
tection in 6-OHDA-treated midbrain cell cultures [10].
The importance of GDNF for dopaminergic neurons survival is well-
documented, aswell as the beneﬁcial effects in the adult brain, therefore
this factor is considered a promising therapeutic agent for PD patients
and has attracted generalized interests during the last decades. Never-
theless, GDNF is unable to cross the blood–brain barrier [32], rising
the relevance of investigating new targets suitable to promote endoge-
nous GDNF expression that can represent a useful tool to develop
promising therapies.
In the present study we investigated whether activation of the
GPER is able to regulate GDNF expression and protect dopaminergic
neurons. For this purpose, we evaluated the effect of G1 and G15 in
rat midbrain neuron–glia cultures challenged with the MPTP active
metabolite, 1-methyl-4-phenylpyridinium (MPP+). In addition, to
further understand the relation between changes in GDNF expres-
sion and the protection exerted by GPER activation, we assessed
the effects of GDNF neutralization and silencing using the same
approach.
2. Material and methods
2.1. Animals
All experiments with animals were performed in accordance with
the national ethical requirements for animal research, and in accor-
dance with the European Convention (Directive 2010/63/EU) and the
council on the protection of animals used for experimental and other
scientiﬁc proposed. All animals were housed in appropriate cages and
maintained at 22 °C, under a 12 h light/12 h dark cycle, with food and
water freely available.
2.2. Mesencephalic neuron–glia cultures
The ventral mesencephalon cells were obtained fromWistar rat em-
bryoswith 15–16 day gestation as previously described by Campos et al.
[10] with some modiﬁcations. Brieﬂy, the pregnant females were anes-
thetized with ketamine (87.5 mg/kg) and xylazine (12.5 mg/kg). The
abdominal cavity was opened and the embryos removed. The embryos
were placed in a petri dish with cold phosphate buffered saline (PBS;
140 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4 and 8.1 mM Na2HPO4,
pH7.4). The dissected tissuewas then transferred to a digestion solution
(trypsin 4.5 mg/ml DNAse and 2.5mg/ml diluted in PBS) and incubated
at 37 °C for 4 min. To stop the enzymatic digestion, PBS with 10% fetal
bovine serum (FBS) was added. After washing, the tissue wasmechanically dissociated in PBS. Finally, the cells were resuspended in
neurobasal medium (MNB) (Gibco) supplemented with 2% B27
(Gibco), 0.05 mg/ml glutamine (Sigma), 50 mg/ml gentamicin
(Sigma) and 25 mM glutamate (Sigma) and 10% FBS, and plated onto
3.5-cm2 or 1.9-cm2 wells coated with poly-D-lysine at a density of
115,000 cells/cm2. The culture was maintained in an incubator at
37 °C with a humidiﬁed atmosphere containing 5% CO2 for 6 days.2.3. Cell culture treatments
Twelve hours before stimulation of the cells, the medium was
replaced by serum-free MNB. The culture was incubated with 17-β
estradiol (100 nM), G1 (100 nM, Calbiochem) and G15 (100 nM,
Calbiochem) for a total of 48 h, in which the cells were exposed to
with MPP+ (10 μM, Sigma Aldrich) in the last 24 h.
For the neutralization of GDNF, the cultures were incubated with
anti-GDNF antibody (0.4 μg/ml, Santa Cruz Biotechnology) for 48 h.
The application of the antibody was performed twice, 30 min prior to
G1 addition and 60 min before MPP+ treatment.
In all the experiments, the cultures were ﬁnally processed for west-
ern blot of GDNF or tyrosine hydroxylase (TH) immunocytochemistry.2.4. Transfection of GDNF RNA interference (RNAi)
A sequence of sense and anti-sense oligonucleotides corresponding
to the rat GDNF cDNA 5′-ACUGACUUGGGUUUGGGCUACGAAA-3′ was
used for GDNF silencing, in accordance with previous optimization
[10]. First, after 4 days in culture, the medium was replaced by MNB
without FBS and12h later the cellswere incubatedwith 50nMRNAi se-
quence plus 0.006 mg Lipofectamine™ 2000 (Invitrogen; Lipo) in opti-
MEM (Gibco). Six hours later the medium was changed and cells were
exposed to both G1 and MPP+, as described above. The cultures were
then used for TH immunocytochemistry.2.5. Immunocytochemistry
After rinsing, the cells were ﬁxed in 4% paraformaldehyde (PFA) for
10 min. This was followed by permeabilization of the cells with 1%
Triton X-100 in PBS for 5 min. To study the cellular localization of this
receptor, this step was not performed. Non-speciﬁc binding was
blocked by incubating the cells with 20% FBS in PBS with 0.1% Tween
(PBS-T) for 60 min at room temperature. After blocking, the cells were
incubated with primary antibody diluted in PBS-T with 1% FBS, anti-
tyrosine hydroxylase (TH; 1:1000, ab112, Abcam, Cambridge, USA),
anti-microtubule-associated protein 2 (MAP2; 1:500, 20172, Santa
Cruz Biotechnology), anti-glial ﬁbrilar acidic protein (GFAP; 1:200,
Z0334, DAKO, Glostrup, Denmark), anti-GPER (1:200, Santa Cruz
Biotechnology) for 60 min at room temperature. After, the cells were
washed with PBS-T and incubated with the corresponding secondary
antibody, also diluted in PBS-T with 1% FCS and incubated for 1 h at
room temperature. After incubation with the secondary antibody the
cells were washed once with PBS-T, incubated 10 min with 2 mM
Hoechst (Invitrogen, CA, USA). Finally, slides were mounted in ﬂuores-
cence mounting medium (Dako, Glostrup, Denmark). Images were
acquired on an epiﬂuorescence microscope (Axiobserver Z1, Zeiss)
with a 63× objective.
For the quantiﬁcation of TH-immunoreactive cells, we performed
at least 3 experiments with different cell cultures. In each experi-
ment 3–4 coverslips were prepared per experimental condition and
20 ﬁelds/coverslip were analyzed on an epiﬂuorescence micro-
scope (Axiobserver Z1, Zeiss) with a 63× objective. The number
of TH-positive positive was normalized to the total number of nuclei,
assessed with Hoescht 33342 (Invitrogen) staining.
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GDNF protein levels were determined by western blot of cell
extracts obtained after cellular disruption with a lysis buffer (Triton
X-100 1%, 50 mM Tris–HCl, pH 7.5, 10 mM EGTA, 150 mM NaCl), with
protease inhibitors (ﬂuoride 2 mM phenylmethylsulfonyl ﬂuoride,
10 g aprotinin/ul, leupeptin 1 μg/μl), phosphatase inhibitor (Na3PO4,
2 mM), and sodium orthovanadate. After quantiﬁcation of total protein
levels present in extracts, using the Bio-Rad Protein Assay (Bio-Rad,
Hercules, CA, USA), the proteins were denatured by addition of a solu-
tion of 0.5 M Tris–HCl, pH 6.8, 10% (w/v) sodium dodecyl sulfate
(SDS) 10% glycerol, 140 mM 2-mercaptoethanol, and 0.1% (w/v)
bromophenol blue. The amount of extract corresponding to 40 μg pro-
tein was separated by SDS-PAGE and transferred to polyvinylidene
diﬂuoride membranes (Amersham Life Sciences, UK). The membranes
were then blocked with 5% milk powder in TBS-T (0.1% Tween-20 in a
20 mM Tris and 137 mM NaCl solution) for 1 h at room temperature.
After blocking, the membranes were incubated with the primary an-
tibody, rabbit anti-GDNF (1:500, Santa Cruz Biotechnology) diluted
in TBS-T, overnight at 4 °C. After being washed with TBS-T, the mem-
branes were incubated for 1 h at room temperature with anti-rabbit
secondary antibody (1:20,000, Amersham Life Sciences) diluted in
TBS-T. Immunoreactivity was detected by exposure of the mem-
branes to the substrate Luminata Growing™Western Chemilumi-
nescent HRP and the signal was detected with Hyperﬁlm–ECL ﬁlm
(Amersham Pharmacia Biotech, Freiburg Germany). The ﬁlms were
scanned and densitometric analysis was performed using the Quan-
tity One software (Bio-Rad).Fig. 1. Expression of GPER in ventral midbrain neuron–glia cell cultures. Primary ventral mid
Hoescht staining. Representative photomicrographs were obtained using an LSM 710 confocal2.7. Total RNA extraction and reverse transcription
Total RNA extraction from cell cultures was performed using the TRI
reagent® (0.1 ml/cm2; Invitrogen) according to the manufacturer's in-
structions. The isolated RNA was dissolved in 15 μl diethylpyrocarbonate-
treated water and stored at−80 °C until use. Total RNA in each sample
was quantiﬁed using UV spectrophotometry at 260 nm (NanoPhotometer,
Implen). RNA quality was determined by measuring the ratio of absor-
bance at 260 nm and 280 nm. RNA integrity was assessed by ethidium
bromide agarose gel (1%) electrophoresis. Single-stranded cDNAs were
synthesized by incubating total RNA (1 μg) for 5 min at 65 °C in a 10 μl
mixture containing 0.03 μg/μl random primers (Invitrogen) and 1 mM
dNTPs (dATP, dCTP, dGTP and dTTP; Thermo Fisher Scientiﬁc). A sec-
ond 8 μl mixture containing 12.5 U/μl Moloney Murine Leukemia
Virus (M-MLV) reverse transcriptase (Invitrogen), diluted in 125 mM
Tris–HCl, pH 8.3, 187.5 mM KCl, 7.5 mMMgCl2 and 25 mM dithiothre-
itol, was then added to the ﬁrst mixture and allowed to incubate for
10 min at 25 °C, 1 h at 37 °C and 15 min at 75 °C. All cDNA samples
were stored at−20 °C until use.
2.8. Real-time PCR
GDNFmRNA levels were analyzed by real-time PCR using the iCycler
IQTM Real-Time PCR Detection System (Bio-Rad). For control purposes,
the expression of cyclophilin a was also monitored. The sequences of
PCR primers (STAB Vida) were as follows: GDNF forward primer-5′
GACTTGGGTTTGGGCTACGAA3′; GDNF reverse primer-5′ATTGTCTCGG
CCGCTTCAC3′; cyclophilin A forward primer 5′CAAGACTGAGTGGCTGbrain cultures were analyzed for GPER, MAP2, TH and GFAP immunocytochemistry, and
microscope (Zeiss) and a 63× objective.
Fig. 3. Regulation of glial cell line-derived neurotrophic factor (GDNF) expression by G1 in
midbrain neuron–glia cultures. The cells were incubated with E2 (100 nM), G1 (100 nM)
or G15 (100 nM) for 48 h.GDNFprotein levelswere analyzedbywestern blotting andden-
sitometric analysis of the bands. Data shown are expressed as percentage of control and
represent themean± SEMof three independent experiments performed in triplicate. Sta-
tistical analysis was performed using one-way ANOVA test followed by Bonferroni post-
test. *p b 0.05 and **P b 0.01 compared with the control.
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AGAG3′. The reactions were carried out using 1 μl of cDNA in a 20 μl re-
action containing 10 μl Maxima SYBR Green/ROX qPCR Master Mix
(Fermentas, Thermo Fisher Scientiﬁc) and 6 pmol of each pair of
primers. The thermal cycling conditions consisted of 10 min at 95 °C,
followed by 40 cycles at 95 °C for 15 s and 60 °C for 1min. Every reaction
was performed in duplicate. The ﬂuorescence was measured after each
cycle. Themelting curveswere performed by heating the reactions from
55 °C to 95 °C at a rate of 0.05 °C/s, with continuous ﬂuorescence
measurement. All primers were validated by quantitative real-time
PCR reactions with decreasing cDNA concentrations (1; 1:10; 1:100)
and the reaction efﬁciencies were calculated. GDNF mRNA levels were
normalized to those of cyclophilin A and expressed relative to the
control condition using the 2− ΔΔCT method.
2.9. Statistical analysis
Data are expressed as percentages of values obtained in control con-
ditions or as percentages of the total number of cells, and are presented
as the mean ± SEM of at least three independent experiments, per-
formed in triplicate. Statistical analysis was performed using one-way
ANOVA followed by Bonferroni's test for experiments involving only
one variable, as appropriate. To determine the effect of G1 and MPP+
treatments the datawere analyzed by two-way analysis of variance. Dif-
ferences between groupswere further analyzed by the Bonferroni's post
test. Values of p b 0.05 were considered signiﬁcant. All statistical proce-
dures were performed using GraphPad Prism v. 4 (GraphPad Software
Inc., San Diego, CA).
3. Results
3.1. GPER localization on the cells of the ventral mesencephalon
It has been shown that the dopaminergic protection exerted by es-
tradiol involves the interaction between neurons and astrocytes [10].
In order to determine whether this protection may involve the action
of GPER, we started by assessing the presence of this receptor in mid-
brain neuron–glia mixed cultures by immunocytochemistry. Immuno-
cytochemistry analysis conﬁrmed the presence of GPER in the cells
positive for the neuronal marker protein used, MAP2 and also in cells
positive for dopaminergic marker, TH and the astrocytic marker, GFAPFig. 2. Effect of 17β-estradiol (E2), GPER selective agonist (G1) and antagonist (G15) on
MPP+-challenged midbrain cultures. Neuron–glia cultures were pretreated with E2
(100 nM), G1 (100 nM) or G15 (100 nM) and 24 h later challenged with MPP+ (10 μM)
for additional 24 h. Cell cultures were processed for TH immunocytochemistry and
TH-positive cell counting. The results were expressed as percentage of control and
represent the mean ± SEM of 3–4 independent experiments performed in triplicate.
Statistical analysis was performed using two way ANOVA test followed by Bonferroni
post test. *P b 0.05 compared with the control; ##P b 0.01 when compared with
MPP+, ++ when compared with E2 + MPP+.(Fig. 1), suggesting that, in this culture, GPER is expressed either by
neurons and astrocytes.
3.2. Activation of GPER prevents loss of mesencephalic dopaminergic
neurons induced by MPP+
There is consistent evidence pointing to the contribution of a mem-
brane receptor in dopaminergic neuroprotection exerted by estradiol
[10,33]. Using midbrain cultures we assessed whether this protection
involves activation of GPER. Exposure to MPP+ caused a reduction of
54.5% on the number of TH-positive cells and the pre-incubation of
the neuron–glia cultures with 17β-estradiol for 24 h before incubation
withMPP+ not only prevented theMPP+-induced loss of dopaminergic
neurons but also caused a 41% increase in the number of these cells rel-
ative to control. To evaluate the involvement of GPER on the observed
protection, the same experiment procedure was used in the presence
of GPER agonist instead of 17β-estradiol. Pre-treatment with G1Fig. 4. Effects of GDNF neutralization on G1-mediated neuroprotection of dopaminergic
neurons exposed to MPP+. Neuron–glia cultures were pretreated with G1 (100 nM) and
later incubated with MPP+ (10 μM) for 24 h in the presence or in absence of an anti-
GDNF. Cell cultures were processed TH immunocytochemistry and TH-positive cell
counting. The results were expressed as percentage of control and represent the
mean± SEM of at least three independent experiments performed in triplicate. Statistical
analysis was performed using two-way ANOVA test followed by Bonferroni post test
***P b 0.001 when compared to control; ##P b 0.01 compared to MPP+; $$b0.01 when
compared to anti-GDNF, ++P b 0.001 compared with G1 + MPP+.
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and similarly to the observed with estradiol, even surpassed control
levels (122.8% of control, Fig. 2). To further verify the importance of
GPER activation in the neuroprotection mediated by 17β-estradiol,
cells were incubated with 17β-estradiol in the presence of the GPER
antagonist (G15). In the presence of G15, the ability of 17β-estradiol
to protect dopaminergic neurons from injury induced by MPP+ was
compromised, with a reduction of 50.1% in the number of TH-positive
cells. Exposure of cells to 17β-estradiol, G1 or G15 alone (in the absence
of injury) did not affect the number of TH-positive cells when compared
to control.
3.3. Regulation of GDNF expression by GPER activation
In our previous study we showed that 17β-estradiol has the ability
to promote GDNF expression both in in vivo and in vitromodels, more-
over GDNF increase is crucial to 17β-estradiol induced dopaminergic
neuroprotection [10]. In the present study, we assessed whether activa-
tion of the GPER can modulate the GDNF expression on midbrain
neuron–glia mixed cultures. For that, cells were treated for 48 h withFig. 5. Effects of GDNF knockdown on dopaminergic neuroprotection provided byGPER activati
Lipofectamine 2000 (Lipo) and GDNF RNAi, pretreated with G1 (100 nM) and, after 24 h, inc
cyclophilin A mRNA levels were measured by real-time PCR. Relative changes in GDNF gene ex
of GDNF mRNA levels relative to control, after normalization to cyclophilin A, and are the mea
after GDNF RNAi. Extracts from neuron–glia cultures were prepared for Western blot analysis
the mean ± SEM of three independent experiments performed in triplicate. C — cell cultures
of control and represent the mean ± SEM of at least three independent experiments perfo
ANOVA test (C) followed by Bonferroni post test *P b 0.05 when compared to control, *P b 0.05
pared to MPP+, $P b 0.05 when compared to RNAi GDNF, ++P b 0.01 when compared to G1 +17β-estradiol, G1 and G15 plus 17β-estradiol, all at a concentration
of 100 nM, and GDNF levels were evaluated by western blot. The
GDNF levels were signiﬁcantly increased with 17β-estradiol and
G1, with an increase of 296% and 200%, respectively, when compared
to control, whereas in the presence of G15 the increase promoted by
17β-estradiol was prevented (Fig. 3).
3.4. Role of GDNF on dopaminergic neuroprotection mediated by GPER
activation
To determine how the GDNF up-regulation induced by GPER
activation contributes to the dopaminergic neuroprotection we
immunodepleted GDNF from the medium. GDNF depletion ham-
pered the G1 ability to protect dopaminergic neurons from MPP+-
induced lesion, leading to a reduction of TH-positive cells from 94%
in cells treated with G1 plus MPP+ to 62% in cultures subjected to
the same treatment but in the presence of GDNF antibody (Fig. 4).
To further conﬁrm the results obtained with GDNF neutralization,
we used RNAi-mediated GDNF knockdown to evaluate the role of
GDNF-increased by GPER activation, in neuroprotective effects.on in neuron–glia cultures treatedwithMPP+. Neuron–glia cultureswere transfectedwith
ubated with MPP+ (10 μM) for further 24 h. A — total RNA was isolated and GDNF and
pression were calculated using the 2− ΔΔCT method. Data are expressed as percentage
n ± SEM. of 3 experiments performed in triplicate. B — reduction of GDNF protein levels
of GDNF protein levels. Data shown are expressed as percentage of control and represent
were processed for TH immunocytochemistry. The results were expressed as percentage
rmed in triplicate. Statistical analysis was performed using one (A and B) or two-way
when compared to control, ***P b 0.001when compared to control, ##P b 0.01when com-
MPP+.
2040 A. Bessa et al. / Biochimica et Biophysica Acta 1852 (2015) 2035–2041RNAi efﬁciency was conﬁrmed by assessing GDNFmRNA and protein
knockdown (Fig. 5A and B). G1-mediated protection of dopaminer-
gic neurons was signiﬁcantly reduced by GDNF knockdown from
84% TH-positive cells in cultures pre-treated with G1 24 h before
MPP+ addition to 46% in cultures knockdown for GDNF and receiving
the same treatment (Fig. 5C). These results strongly support the
involvement of GDNF up-regulation in dopaminergic neuroprotec-
tive effects triggered by GPER activation.4. Discussion
First, we were successful to conﬁrm the presence of the new mem-
ber of the ER family, GPER, in midbrain neuron–glia cultures, a result
in accordance with previous data showing GPER-immunoreactivity in
SNc [14]. Moreover, our results also indicate that GPER is localized in
the plasma membrane as have been described for CA2 pyramidal neu-
rons of the hippocampus in the rat [12]. Importantly, the presence of a
membrane ER in midbrain cell cultures support our previous ﬁnding
suggesting that 17β-estradiol actions on GDNF levels are not triggered
by the activation of the classical nuclear ER [10]. To further explore
the importance of GPER activation in GDNF expression regulation, we
started by demonstrating the involvement of GPER in 17β-estradiol-
mediated protection of dopaminergic neurons against MPP+ toxicity.
We showed that selective activation of GPER with the G1 agonist is as
effective as 17β-estradiol to protect dopaminergic neurons from
MPP+, in midbrain neuron–glia cultures. This ﬁnding was corroborated
by the complete prevention of 17β-estradiol-induced neuroprotection
in the presence of the GPER antagonist G15.
Our results showing the importance of GPER activation in dopami-
nergic neuroprotection from MPP+-induced toxicity are in agreement
with an in vivo study reporting the same neuroprotective effects in a
MPTP mouse model of PD [25]. While our study shows that G15
completely inhibited the neuroprotective effects of 17β-estradiol that
demonstrate the pivotal role of GPER activation, the classical ERα has
been also implicated in 17β-estradiol-induced neuroprotection [34],
suggesting a convergent neuroprotective effect of both ERα and GPER
that can be inﬂuenced by receptors' distribution on the brain.
The ability of estrogens to modulate the expression of neuroprotec-
tive agents, namely the potent dopaminergic survival factor, GDNF, has
been proven in bothmidbrain and hypothalamic cultures [10,26]. Here-
in, we found that GPER activation promotes a marked increase in GDNF
expression, in midbrain cell cultures, close to the up-regulation pro-
duced by 17β-estradiol. Of note, these ﬁndings support our previous
data indicating that 17β-estradiol-induced increase of GDNF levels
through a membrane associated receptor [10]. Taken together, these
ﬁndings point out to a role of GPER activation in 17β-estradiol-
mediated GDNF up-regulation responsible by dopaminergic neuropro-
tection. In addition, GDNF neutralization and RNAi-mediated GDNF
knockdown experiments were of major importance to prove the contri-
bution of GDNF as a mediator of neuroprotective effects generated by
GPER activation. In midbrain neuron–glia cultures, we showed that a
decrease of GDNF levels prevented the G1-mediated neuroprotective
effects against MPP+ toxicity.
Regarding GPER and GDNF signaling, it is interesting the apparent
overlap of triggered signaling pathways, namelymitogen-activated pro-
tein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and phospho-
lipase C (PLC) [35–37]. Our results showed that speciﬁc inhibition of
these pathways results in the prevention of G1-induced neuroprotec-
tion (see Supplementary data, Fig. S1). The dependence on the activa-
tion of these signaling pathways for the neuroprotective effects
provides strong evidences of a synergistic action of GPER and GDNF.
To our knowledge, this study is the ﬁrst one to provide evidence
that GDNF up-regulation is crucial for GPER-mediated dopaminergic
protection. Overall, our data support the idea that GPER activation
might be a promising alternative to reproduce the neuroprotectiveeffects of 17β-estradiol, which are attributed to GDNF up-regulation,
with the advantage of being a nonfeminizing agent [10,20].
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.07.004.
Transparency document
The Transparency document associated with this article can be
found, in the online version.
Acknowledgments
The authors acknowledge the support from the Portuguese Foundation
for Science and Technology through the COMPETE program (grant PEst-C/
SAU/UI0709/2011) and PTDC/NEU-BEN/0156/2012, and to Programa
Operacional Regional do Centro 2007–2013 QREN (CENTRO-07-ST24-
FEDER-002015).
References
[1] K.E. Lyons, J.P. Hubble, A.I. Troster, R. Pahwa, W.C. Koller, Gender differences in
Parkinson's disease, Clin. Neuropharmacol. 21 (1998) 118–121.
[2] J.F. Kurtzke, I.D. Goldberg, Parkinsonism death rates by race, sex, and geography,
Neurology 38 (1988) 1558–1561.
[3] R.H. Swerdlow,W.D. Parker, L.J. Currie, J.P. Bennett, M.B. Harrison, J.M. Trugman, G.F.
Wooten, Gender ratio differences between Parkinson's disease patients and their
affected relatives, Parkinsonism Relat. Disord. 7 (2001) 129–133.
[4] R. Saunders-Pullman, J. Gordon-Elliott, M. Parides, S. Fahn, H.R. Saunders, S.
Bressman, Theeffect of estrogen replacementonearly Parkinson's disease,Neurology
52 (1999) 1417–1421.
[5] B. Liu, D.E. Dluzen, Oestrogen and nigrostriatal dopaminergic neurodegeneration:
animal models and clinical reports of Parkinson's disease, Clin. Exp. Pharmacol.
Physiol. 34 (2007) 555–565.
[6] D.E. Dluzen, J.L. McDermott, B. Liu, Estrogen as a neuroprotectant against MPTP-
induced neurotoxicity in C57/B1 mice, Neurotoxicol. Teratol. 18 (1996) 603–606.
[7] A.D. Ramirez, X. Liu, F.S. Menniti, Repeated estradiol treatment prevents MPTP-
induced dopamine depletion in male mice, Neuroendocrinology 77 (2003)
223–231.
[8] H.E. Murray, A.V. Pillai, S.R. McArthur, N. Razvi, K.P. Datla, D.T. Dexter, G.E. Gillies,
Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the
nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen
in males and females, Neuroscience 116 (2003) 213–222.
[9] S. Callier, M. Le Saux, A.M. Lhiaubet, T. Di Paolo, W. Rostene, D. Pelaprat, Evaluation
of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine
and 1-methyl-4-phenylpyridinium ion (Mpp+) towards dopaminergic mesence-
phalic neurones in primary culture, J. Neurochem. 80 (2002) 307–316.
[10] F.L. Campos, A.C. Cristovao, S.M. Rocha, C.P. Fonseca, G. Baltazar, GDNF con-
tributes to oestrogen-mediated protection of midbrain dopaminergic neurones,
J. Neuroendocrinol. 24 (2012) 1386–1397.
[11] H.S. Taylor, J.E. Manson, Update in hormone therapy use in menopause, J. Clin.
Endocrinol. Metab. 96 (2011) 255–264.
[12] T. Funakoshi, A. Yanai, K. Shinoda, M.M. Kawano, Y. Mizukami, G protein-coupled
receptor 30 is an estrogen receptor in the plasma membrane, Biochem. Biophys.
Res. Commun. 346 (2006) 904–910.
[13] R. Hammond, D. Nelson, R.B. Gibbs, GPR30 co-localizes with cholinergic neurons in
the basal forebrain and enhances potassium-stimulated acetylcholine release in the
hippocampus, Psychoneuroendocrinology 36 (2011) 182–192.
[14] E. Brailoiu, S.L. Dun, G.C. Brailoiu, K. Mizuo, L.A. Sklar, T.I. Oprea, E.R. Prossnitz, N.J.
Dun, Distribution and characterization of estrogen receptor G protein-coupled
receptor 30 in the rat central nervous system, J. Endocrinol. 193 (2007) 311–321.
[15] C. Otto, B. Rohde-Schulz, G. Schwarz, I. Fuchs, M. Klewer, D. Brittain, G. Langer, B.
Bader, K. Prelle, R. Nubbemeyer, K.H. Fritzemeier, G protein-coupled receptor 30 lo-
calizes to the endoplasmic reticulumand is not activated by estradiol, Endocrinology
149 (2008) 4846–4856.
[16] E.R. Prossnitz, J.B. Arterburn, H.O. Smith, T.I. Oprea, L.A. Sklar, H.J. Hathaway, Estro-
gen signaling through the transmembrane G protein-coupled receptor GPR30,
Annu. Rev. Physiol. 70 (2008) 165–190.
[17] U.E. Martensson, S.A. Salehi, S. Windahl, M.F. Gomez, K. Sward, J. Daszkiewicz-
Nilsson, A. Wendt, N. Andersson, P. Hellstrand, P.O. Grande, C. Owman, C.J. Rosen,
M.L. Adamo, I. Lundquist, P. Rorsman, B.O. Nilsson, C. Ohlsson, B. Olde, L.M. Leeb-
Lundberg, Deletion of the G protein-coupled receptor 30 impairs glucose tolerance,
reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated
insulin release in female mice, Endocrinology 150 (2009) 687–698.
[18] J. Isensee, L. Meoli, V. Zazzu, C. Nabzdyk, H. Witt, D. Soewarto, K. Effertz, H. Fuchs, V.
Gailus-Durner, D. Busch, T. Adler, M.H. de Angelis, M. Irgang, C. Otto, P.R. Noppinger,
Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice, Endocri-
nology 150 (2009) 1722–1730.
[19] C.Wang, B. Dehghani, I.J. Magrisso, E.A. Rick, E. Bonhomme, D.B. Cody, L.A. Elenich, S.
Subramanian, S.J. Murphy, M.J. Kelly, J.S. Rosenbaum, A.A. Vandenbark, H. Offner,
2041A. Bessa et al. / Biochimica et Biophysica Acta 1852 (2015) 2035–2041GPR30 contributes to estrogen-induced thymic atrophy, Mol. Endocrinol. 22 (2008)
636–648.
[20] C. Otto, I. Fuchs, G. Kauselmann, H. Kern, B. Zevnik, P. Andreasen, G. Schwarz, H.
Altmann, M. Klewer, M. Schoor, R. Vonk, K.H. Fritzemeier, GPR30 does not mediate
estrogenic responses in reproductive organs in mice, Biol. Reprod. 80 (2009) 34–41.
[21] S.B. Liu, N. Zhang, Y.Y. Guo, R. Zhao, T.Y. Shi, S.F. Feng, S.Q. Wang, Q. Yang, X.Q. Li,
Y.M. Wu, L. Ma, Y. Hou, L.Z. Xiong, W. Zhang, M.G. Zhao, G-protein-coupled receptor
30 mediates rapid neuroprotective effects of estrogen via depression of NR2B-
containing NMDA receptors, J. Neurosci. 32 (2012) 4887–4900.
[22] D. Lebesgue, M. Traub, M. De Butte-Smith, C. Chen, R.S. Zukin, M.J. Kelly, A.M. Etgen,
Acute administration of non-classical estrogen receptor agonists attenuates
ischemia-induced hippocampal neuron loss in middle-aged female rats, PLoS One
5 (2010) e8642.
[23] S. Gingerich, G.L. Kim, J.A. Chalmers, M.M. Koletar, X. Wang, Y. Wang, D.D. Belsham,
Estrogen receptor alpha and G-protein coupled receptor 30 mediate the neuropro-
tective effects of 17beta-estradiol in novel murine hippocampal cell models, Neuro-
science 170 (2010) 54–66.
[24] H. Tang, Q. Zhang, L. Yang, Y. Dong, M. Khan, F. Yang, D.W. Brann, R. Wang, Reprint
of “GPR30 mediates estrogen rapid signaling and neuroprotection”, Mol. Cell.
Endocrinol. 389 (2014) 92–98.
[25] M. Bourque, M. Morissette, M. Cote, D. Soulet, T. Di Paolo, Implication of GPER1 in
neuroprotection in a mouse model of Parkinson's disease, Neurobiol. Aging 34
(2013) 887–901.
[26] T. Ivanova, M. Karolczak, C. Beyer, Estradiol stimulates GDNF expression in develop-
ing hypothalamic neurons, Endocrinology 143 (2002) 3175–3178.
[27] T. Ivanova, E. Kuppers, J. Engele, C. Beyer, Estrogen stimulates brain-derived neuro-
trophic factor expression in embryonic mouse midbrain neurons through a
membrane-mediated and calcium-dependent mechanism, J. Neurosci. Res. 66
(2001) 221–230.[28] L. Pietranera, A. Lima, P. Roig, A.F. De Nicola, Involvement of brain-derived neuro-
trophic factor and neurogenesis in oestradiol neuroprotection of the hippocampus
of hypertensive rats, J. Neuroendocrinol. 22 (2010) 1082–1092.
[29] R.B. Gibbs, Treatment with estrogen and progesterone affects relative levels of
brain-derived neurotrophic factor mRNA and protein in different regions of the
adult rat brain, Brain Res. 844 (1999) 20–27.
[30] F. Sohrabji, D.K. Lewis, Estrogen–BDNF interactions: implications for neurodegener-
ative diseases, Front. Neuroendocrinol. 27 (2006) 404–414.
[31] C.D. Toran-Allerand, R.C. Miranda, W. Bentham, F. Sohrabji, T.J. Brown, R.B.
Hochberg, N.J. MacLusky, Estrogen receptors colocalize with low-afﬁnity nerve
growth factor receptors in cholinergic neurons of the basal forebrain, Proc. Natl.
Acad. Sci. 89 (1992) 4668–4672.
[32] A.J. Kastin, V. Akerstrom,W. Pan, Glial cell line-derived neurotrophic factor does not
enter normal mouse brain, Neurosci. Lett. 340 (2003) 239–241.
[33] E.J. Filardo, P. Thomas, GPR30: a seven-transmembrane-spanning estrogen receptor
that triggers EGF release, Trends Endocrinol. Metab. 16 (2005) 362–367.
[34] S. Al Sweidi, M.G. Sanchez, M. Bourque, M. Morissette, D. Dluzen, T. Di Paolo,
Oestrogen receptors and signalling pathways: implications for neuroprotective
effects of sex steroids in Parkinson's disease, J. Neuroendocrinol. 24 (2012) 48–61.
[35] C.P. Fonseca, S. Gama, A. Saavedra, G. Baltazar, H2O2- or l-DOPA-injured dopaminer-
gic neurons trigger the release of soluble mediators that up-regulate striatal GDNF
through different signalling pathways, Biochim. Biophys. Acta 1842 (2014) 927–934.
[36] D. Poteryaev, A. Titievsky, Y.F. Sun, J. Thomas-Crusells, M. Lindahl, M. Billaud, U.
Arumae, M. Saarma, GDNF triggers a novel ret-independent Src kinase family-
coupled signaling via a GPI-linked GDNF receptor alpha1, FEBS Lett. 463 (1999)
63–66.
[37] C.M. Revankar, D.F. Cimino, L.A. Sklar, J.B. Arterburn, E.R. Prossnitz, A transmem-
brane intracellular estrogen receptor mediates rapid cell signaling, Science 307
(2005) 1625–1630.
